冠心病患者经皮冠状动脉介入术后主要心血管不良事件研究进展  

research progress on the pathogenesis of MACE after coronary heart disease

作　　者：肖立运(综述) 郝影影(审校) XIAO Liyun;HAO Yingying(Emergency Department of Jining First People′s Hospital,ining 272000,China;Jining North Lake Provincial Tourism Resort People′s Hospital Cardiology Department,Jining 272000,China)

机构地区：[1]济宁市第一人民医院急诊科,济宁272000 [2]济宁北湖省级旅游度假区人民医院心内科,济宁272000

出　　处：《济宁医学院学报》2024年第5期439-442,共4页Journal of Jining Medical University

基　　金：济宁市重点研发基金资助项目(2019MNS021;2022YXNS131);山东省中医药科技发展计划项目(2019-0454)。

摘　　要：经皮冠状动脉介入术(percutaneous coronary intervention,PCI)是治疗急性冠状动脉综合征(acute coronary syndrome,ACS)的主要手段之一。PCI后,仍有部分冠心病患者出现主要心血管不良事件(major adverse cardiovascular events,MACE),再次影响其心功能及术后生存质量,严重甚至可危及生命安全。本文通过中医及现代分子生物学视角下深入探索冠心病PCI后MACE可能机制,对中西医结合防治PCI后MACE有着重要的意义。Percutaneous coronary intervention(PCI)is one of the primary treatments for acute coronary syndrome(ACS).After PCI,some patients with coronary heart disease still experience major adverse cardiovascular events(MACE),which can adversely affect their cardiac function and postoperative quality of life,and in severe cases,may even jeopardize their safety.This article delves into the possible mechanisms of MACE in coronary heart disease patients after PCI from the perspectives of traditional Chinese medicine and modern molecular biology,which has significant implications for the prevention and treatment of MACE through the integration of traditional Chinese and Western medicine.

关 键 词：经皮冠状动脉介入术 主要心血管不良事件 痰瘀互阻 血小板聚集 脂质代谢 易损斑块 炎症反应 

分 类 号：R459.9[医药卫生—治疗学]